NIH AI Restriction
NIH policy NOT-OD-25-132 prohibits the use of AI-generated text in grant applications that is not substantially modified by the applicant. All AI-drafted sections must be thoroughly rewritten in your own words before submission.
View full policyRigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research
National Institutes of Health
About This Grant
<p>The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium major efforts will be devoted to: 1) Harmonize established assays for biomarkers such as HbA1c and c-peptide, making sure that these assays are performed in a rigorous and reproducible manner in the clinical research community and in clinical practice. For this purpose, reference methods and materials will use a metrology approach and will be made available to the community; 2) Identify and validate other biomarkers that can be used for the prevention, diagnosis, and clinical management of T1D. It has been reported that the assays for several biomarkers routinely used in clinical research such as glucagon, amylin, chromogranin, insulin, pro-insulin and other pro-hormones are not reproducible across platforms or laboratories. For this purpose, this consortium will ensure that all assays for biomarkers routinely used in clinical research and for newly identified biomarkers are rigorously validated and assessed for reproducibility across several laboratories following a metrology approach. </p>
Grant Summary
Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research is a National Institutes of Health grant providing funding that varies by award for small business, university, municipality. Applications are due 2026-06-25 (closing in 2 days). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
- Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to Apply
Up to $0K
2026-06-25
- 1Confirm your organization is eligible for Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research from National Institutes of Health, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to National Institutes of Health before the deadline.
Search & build free — $99 one-time to unlock the export-ready application pack. No subscription.
Don't want to draft it yourself?
We'll draft the complete application against National Institutes of Health's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research: Frequently Asked Questions
Who is eligible for the Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research?
Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research is offered by National Institutes of Health and is generally open to small business, university, municipality, tribal government, nonprofit, school district. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research provide?
Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research provides an amount that varies by award per award from National Institutes of Health. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research deadline?
Applications for Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research are due 2026-06-25 (closing in 2 days). Because deadlines can change, verify the date with the funder, National Institutes of Health, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research?
To apply for Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from National Institutes of Health.